Contrast developer Bracco Diagnostics has begun commercial shipments of its MultiHance gadolinium-based MR contrast agent.
The company's president and chief executive officer, Carlo Medici, delivered the first commercial shipment of the product to Dr. Martin Prince of Weill Cornell MRI, who played a key role in the development and research of the product, according to the Princeton, NJ-based firm.
By AuntMinnie.com staff writers
February 8, 2005
Related Reading
Bracco gets FDA nod for MultiHance, November 24, 2004
SonoVue reinstated for echo use, November 1, 2004
Berlex, Bracco, E-Z-EM, PETNet form consortium, September 27, 2004
CHMP recommends SonoVue reinstatement, August 5, 2004
Bracco clarifies SonoVue restrictions, May 24, 2004
Copyright © 2005 AuntMinnie.com
